Huge bull and long $PRME
A very good asymmetrical bet long term imo that may revolutionize medicine’s approach to many genetic diseases.
I totally get checking price daily and wanting to see green (often guilty personally), yet I really think this is a play where you keep up with company updates, data releases and overall operations including finances and ignore price. Disregarding traders, I doubt many here are investing with a goal of a traditional solid return. Long winded way of saying , volatility should largely be ignored here with exceptions of trying to strategically increase position , distribute shares or swing shares. Embrace the volatility 🔥
* also buy when David buys 😉
https://t.co/L1W3cJIiB0
This interview of Jake Van Naarden $LLY head of corporate business development, by @angelicapeebles - CNBC’s excellent Pharma reporter, has demonstrated once again just how far-sighted Eli Lilly’s strategy really is and how it helps Eli Lilly to strengthen its dominance in the BioTech and Pharma ecosystem. I was especially interested to learn more about the rationale behind Eli Lilly’s staggering deal-making pace and that there is much more to come M&A-wise. Definitely worth your time! $XBI
@pakkbuilderd@ThierryBorgeat 💯
It may require tech to crash.. your points are good, I do not understand it either. NOC also gets no respect for their space program. Confident long term still.
@RonDeSantis Absolutely pathetic. Whether democratic or republican, this level of incompetence is indefensible. Also won’t help those who do not trust the system already.
@_OliverVenture I’m crossing my fingers. My skeptical side knows he stated this IND would be approved in 2023 (NOT A TYPO). I hope IPSC doesn’t fall into this pattern, they affirmed guidance of IND before EOY.
@PatternNotes 🔥 Excellent. Having kids, I believe shaping how kids think and reason is a skill that is incredibly important and should be stressed more than just about anything.